Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
MedTech
DNA and RNA testing helps identify blood cancer relapse risks
Researchers have found a dual genetic test is more accurate in identifying relapse risks for certain patients with blood cancer.
Ben Adams
Oct 13, 2025 10:00am
BMS reports phase 3 win in multiple myeloma
Sep 23, 2025 8:20am
AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer
Jul 10, 2025 9:01am
Biotech shares first data for in vivo CAR-T that attracted AZ
Jul 7, 2025 2:27pm
Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial
May 19, 2025 9:25am
C4T halts BRAF degrader work to save cash for cemsidomide
May 7, 2025 7:00am
